BMC cancer, 2022-04-28, Vol.22 (1), p.468-468
Research in treatment of non-small cell lung cancer (NSCLC) has shown promising results with stereotactic ablative radiotherapy (SABR) of oligometastatic disease, wherein distant disease may be limited to one or a few distant organs by host factors. Traditionally, PET/CT has been used in detecting metastatic disease and avoiding futile surgical intervention, however, sensitivity and specificity is limited to only 81 and 79%, respectively. Mediastinal staging still identifies occult nodal disease in up to 20% of NSCLC patients initially thought to be operative candidates. Endobronchial ultrasound and transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive tool for the staging and diagnosis of thoracic malignancy. When EBUS is combined with endoscopic ultrasound using the same bronchoscope (EUS-B), the diagnostic sensitivity and negative predictive value increase to 84 and 97%, respectively. Endoscopic staging in patients with advanced disease has never been studied, but may inform treatment if a curative SABR approach is being taken.
This is a multi-centre, prospective, cohort study with two-stage design. In the first stage, 10 patients with oligometastatic NSCLC (lung tumour ± hilar/mediastinal lymphadenopathy) with up to 5 synchronous metastases will be enrolled An additional 19 patients will be enrolled in the second stage if rate of treatment change is greater than 10% in the first stage. Patients will be subject to EBUS or combined modality EBUS/EUS-B to assess bilateral lymph node stations using a N3 to N2 to N1 progression. Primary endpoint is defined as the rate of change to treatment plan including change from SABR to conventional dose radiation, change in mediastinal radiation field, and change from curative to palliative intent treatment.
If a curative approach with SABR for oligometastatic disease is being explored, invasive mediastinal staging may guide treatment and prognosis. This study will provide insight into the use of endoscopic mediastinal staging in determining changes in treatment plan of NSCLC. Results will inform the design of future phase II trials.
Clinicaltrials.gov identifier NCT04852588. Date of registration: April 19, 2021.
1.1 on December 9, 2021.
Carcinoma, Non-Small-Cell Lung - pathology ; Cohort Studies ; Endobronchial ultrasound (EBUS) ; Endoscopic ultrasound (EUS) ; Humans ; Lung Neoplasms - pathology ; Lung Neoplasms - radiotherapy ; Lymphatic Metastasis - radiotherapy ; Neoplasm Staging ; Non-small cell lung cancer (NSCLC) ; Oligometastatic disease ; Positron Emission Tomography Computed Tomography ; Prospective Studies ; Stereotactic ablative radiotherapy (SABR)
BioMedCentral Open Access
Academic Search Ultimate
DOAJ Directory of Open Access Journals - Not for CDI Discovery
Permalink to record
https://www.ncbi.nlm.nih.gov/pubmed/35484614$$D View this record in MEDLINE/PubMed